David A. Siegel Kura Oncology, Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 442,500 shares of KURA stock, worth $4.48 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

442,500

Previous 278,600 58.83%

Holding current value

$4.48 Million

Previous $1.84 Million 38.9%

% of portfolio

0.01%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$5.55 - $6.92 $909,645 - $1.13 Million	163,900 Added 58.83%	442,500 $2.55 Million
Q1 2025 May 15, 2025	BUY	$6.6 - $9.05 $240,240 - $329,420	36,400 Added 15.03%	278,600 $1.84 Million
Q4 2024 Feb 14, 2025	BUY	$8.51 - $19.21 $1.23 Million - $2.77 Million	144,201 Added 147.15%	242,200 $2.11 Million
Q3 2024 Nov 14, 2024	SELL	$18.57 - $23.23 $310,137 - $387,964	-16,701 Reduced 14.56%	97,999 $1.91 Million
Q2 2024 Aug 14, 2024	BUY	$17.53 - $22.98 $494,346 - $648,036	28,200 Added 32.6%	114,700 $2.36 Million
Q1 2024 May 15, 2024	BUY	$13.42 - $23.53 $870,958 - $1.53 Million	64,900 Added 300.46%	86,500 $1.85 Million
Q4 2023 Feb 14, 2024	SELL	$7.58 - $14.38 $17,434 - $33,074	-2,300 Reduced 9.62%	21,600 $310,000
Q3 2023 Nov 14, 2023	BUY	$8.44 - $11.86 $31,227 - $43,882	3,700 Added 18.32%	23,900 $217,000
Q2 2023 Aug 14, 2023	SELL	$9.62 - $13.99 $223,183 - $324,568	-23,200 Reduced 53.46%	20,200 $213,000
Q1 2023 May 15, 2023	SELL	$10.71 - $14.6 $1.63 Million - $2.22 Million	-151,900 Reduced 77.78%	43,400 $530,000
Q4 2022 Feb 14, 2023	SELL	$11.23 - $16.9 $1.93 Million - $2.9 Million	-171,700 Reduced 46.78%	195,300 $2.42 Million
Q3 2022 Nov 14, 2022	BUY	$12.01 - $19.45 $1.39 Million - $2.26 Million	116,100 Added 46.27%	367,000 $5.01 Million
Q2 2022 Aug 15, 2022	SELL	$10.71 - $18.33 $173,502 - $296,946	-16,200 Reduced 6.07%	250,900 $4.6 Million
Q1 2022 May 16, 2022	SELL	$11.78 - $16.98 $1.86 Million - $2.68 Million	-157,700 Reduced 37.12%	267,100 $4.3 Million
Q4 2021 Feb 14, 2022	SELL	$12.22 - $19.57 $1.99 Million - $3.19 Million	-162,900 Reduced 27.72%	424,800 $5.95 Million
Q3 2021 Nov 15, 2021	SELL	$15.42 - $21.72 $1.71 Million - $2.41 Million	-111,000 Reduced 15.89%	587,700 $11 Million
Q2 2021 Aug 16, 2021	BUY	$20.85 - $29.88 $1.36 Million - $1.95 Million	65,300 Added 10.31%	698,700 $14.6 Million
Q1 2021 May 17, 2021	BUY	$24.75 - $39.14 $3.39 Million - $5.36 Million	137,000 Added 27.6%	633,400 $17.9 Million
Q4 2020 Feb 16, 2021	BUY	$29.0 - $41.62 $9.31 Million - $13.4 Million	320,900 Added 182.85%	496,400 $16.2 Million
Q3 2020 Nov 16, 2020	SELL	$16.3 - $30.64 $1.2 Million - $2.26 Million	-73,600 Reduced 29.55%	175,500 $5.38 Million
Q2 2020 Aug 14, 2020	BUY	$7.95 - $18.81 $56,445 - $133,551	7,100 Added 2.93%	249,100 $4.06 Million
Q1 2020 May 15, 2020	BUY	$6.45 - $14.04 $693,375 - $1.51 Million	107,500 Added 79.93%	242,000 $2.41 Million
Q4 2019 Feb 14, 2020	BUY	$12.97 - $15.94 $1.09 Million - $1.34 Million	84,100 Added 166.87%	134,500 $1.85 Million
Q3 2019 Nov 14, 2019	BUY	$14.75 - $20.87 $194,700 - $275,484	13,200 Added 35.48%	50,400 $765,000
Q2 2019 Aug 14, 2019	BUY	$14.71 - $19.79 $273,606 - $368,094	18,600 Added 100.0%	37,200 $732,000
Q1 2019 May 15, 2019	BUY	$13.73 - $16.87 $59,039 - $72,541	4,300 Added 30.07%	18,600 $309,000
Q4 2018 Feb 14, 2019	BUY	$10.6 - $17.49 $3,180 - $5,246	300 Added 2.14%	14,300 $201,000
Q3 2018 Nov 14, 2018	SELL	$16.65 - $21.85 $63,269 - $83,030	-3,800 Reduced 21.35%	14,000 $245,000
Q2 2018 Aug 14, 2018	BUY	$14.8 - $18.8 $263,440 - $334,640	17,800 New	17,800 $324,000

Others Institutions Holding KURA

# of Institutions

191

Shares Held

79.9M

Call Options Held

53.6K

Put Options Held

42.8K

View Full List

About Kura Oncology, Inc.

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $678M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

More about KURA

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account